Table 3.
Individual antibody responses to MB2 recombinant peptides of the B domain as determined by immunoblot analysis.
| MB2-Aa | MB2-Ba | MB2-Ca | ||||
| Volunteer serum | ||||||
| Volunteer #1 (protected) | - b | ++ b | -/+ b | |||
| Volunteer #3 (protected) | - | ++ | -/+ | |||
| Volunteer #5 (protected) | - | ++ | -/+ | |||
| Volunteer #7 (protected) | - | ++ | -/+ | |||
| WRAIR #1 (protected) | - | ++ | -/+ | |||
| WRAIR #4 (not protected) | - | - | - | |||
| WRAIR #5 (not protected) | - | - | - | |||
| WRAIR #6 (not protected) | - | - | - | |||
|
Kenyan serum Smear negative |
MB2-Aa | MB2-Ba | MB2-Ca |
Age (yrs) |
CSP AUd |
TRAP AUd |
| c KU 036 | - | ++ | + | 29 | 1.77 | 2.35 |
| KU 071 | - | ++ | +++ | 18 | 1.24 | 2.08 |
| KU 081 | - | + | ++ | 34 | 1.01 | 1.23 |
| KU 069 | - | + | ++ | 18 | 0.55 | 1.31 |
| KU 079 | - | -/+ | ++ | 80 | 1.0 | 2.63 |
| KU 083 | - | -/+ | +++ | 45 | 4.28 | 4.80 |
| KU 163 | - | ++ | -/+ | 18 | 1.75 | 1.46 |
| KU 202 | - | - | + | 30 | 2.22 | 2.22 |
| KU 205 | - | -/+ | -/+ | 44 | 1.81 | 1.17 |
| Smear positive, asymptomatic | ||||||
| KU 118 | - | - | - | 23 | 1.94 | 1.85 |
| KU 044 | - | + | - | 6 | 0.75 | 0.79 |
| KU 048 | - | - | + | 6 | 0.61 | 0.62 |
| KU 076 | - | - | -/+ | 6 | 1.29 | 0.72 |
| KU 001 | - | ++ | ++ | 2 | 1.11 | 1.43 |
| KU 049 | - | - | - | 6 | 1.64 | 0.66 |
| KU 025 | - | - | - | 6 | 0.42 | 0.26 |
| Smear positive, symptomatic | ||||||
| KU 064 | - | - | - | 27 | 1.38 | 2.40 |
| KU 070 | - | + | - | 18 | 1.41 | 1.59 |
| KU 157 | - | + | +++ | 20 | 1.64 | 1.37 |
| KU 158 | - | + | ++ | 26 | ND | ND |
| KU 165 | - | - | - | 26 | 0.34 | 0.10 |
| KU 172 | - | -/+ | ++ | 22 | ND | ND |
| KU 199 | - | + | -/+ | 19 | ND | ND |
| KU 203 | - | - | -/+ | 30 | 1.34 | 1.0 |
| KU 207 | - | - | + | 19 | ND | ND |
| KU 234 | - | + | -/+ | 42 | ND | ND |
| KU 162 | - | + | +++ | 6 | ND | ND |
| KU 062 | - | - | - | 6 | 0.87 | 1.85 |
| KU 161 | - | - | -/+ | 7 | 0.67 | 0.88 |
| KU 041 | - | - | -/+ | 6 | 1.62 | 0.71 |
| KU 037 | - | ++ | -/+ | 60 | 1.36 | 1.52 |
| KU 072 | - | -/+ | -/+ | 24 | 0.59 | 1.0 |
| KU 075 | - | + | ++ | 32 | 0.72 | 1.35 |
| KU 080 | - | -/+ | + | 34 | 0.87 | 1.50 |
| KU 088 | - | - | - | 70 | 1.01 | 0.57 |
| KU 145 | - | + | + | 40 | 3.01 | 2.56 |
| KU 155 | - | - | ++ | 37 | 0.53 | 0.38 |
| KU 174 | - | + | + | 22 | 2.27 | 1.90 |
| KU 183 | - | -/+ | ++ | 23 | 0.30 | 0.36 |
| KU 067 | - | - | + | 6 | 1.90 | 2.95 |
| KU 084 | - | ++ | + | 2 | 0.40 | 1.277 |
a Peptides are described in Figure 1. b - no detectable band, -/+ weak band but visible, + weak band, ++ moderate to strong band and +++ intense band on western blot. c KU= serum obtained from individuals living in Kenya d AU = arbitrary units, see Methods for definition. CSP = circumsporozoite protein; TRAP = thrombospondin related adhesive protein.
ND = not determined